Schrodinger SDGR Oncology, Neurology, and Immunology Product — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Schrodinger in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Schrodinger's oncology, neurology, and immunology product — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Schrodinger's oncology, neurology, and immunology product — total revenues?
- Schrodinger (SDGR) reported oncology, neurology, and immunology product — total revenues of $700K in Q1 2026.
- How has Schrodinger's oncology, neurology, and immunology product — total revenues changed year-over-year?
- Schrodinger's oncology, neurology, and immunology product — total revenues increased by 16.7% year-over-year, from $600K to $700K.
- What is the long-term trend for Schrodinger's oncology, neurology, and immunology product — total revenues?
- Over 2 years (2022 to 2024), Schrodinger's oncology, neurology, and immunology product — total revenues has grown at a -30.1% compound annual growth rate (CAGR), from $22.1M to $10.8M.
- What does oncology, neurology, and immunology product — total revenues mean?
- This metric represents the total gross revenue generated from the sale of products or services specifically within the oncology, neurology, and immunology therapeutic areas. It captures the financial performance of these specialized drug discovery and development programs, reflecting the company's ability to monetize its research pipeline in these high-value medical fields. Tracking this revenue stream is essential for assessing the commercial success and market adoption of the company's targeted therapeutic solutions.